Video

The Role of Adjuvant Therapy in Patients with NSCLC

Author(s):

Heather Wakelee, MDBill W. Loo, MD

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Related Videos
Marina Chiara Garassino, MD
Nicolas Girard, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Nicolas Girard, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Shirish M. Gadgeel, MD
Related Content
Eric Kumar Singhi, MD, of MD Anderson Cancer Center
October 9th 2024

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Isabel Preeshagul, DO, MBS, of Memorial Sloan Kettering Cancer Center
October 7th 2024

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology